IGM Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023 07:00 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today...
IGM Biosciences Presents Data from T cell Engager Portfolio for Hematologic Malignancies at 2022 American Society of Hematology Annual Meeting
December 11, 2022 10:00 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., Dec. 11, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today...
IGM Biosciences to Present at the Bank of America Biotech SMID Cap Conference
December 01, 2022 07:00 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today...
IGM Biosciences to Present at Three Upcoming Investor Conferences
November 08, 2022 07:00 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today...
IGM Biosciences Announces Third Quarter 2022 Financial Results and Provides Corporate Update
November 03, 2022 09:05 ET
|
IGM Biosciences, Inc.
– Data from T cell Engager Portfolio for Hematologic Malignancies, Including First Preclinical Data for IGM-2644 and IGM-2537, Selected for Poster Presentations at 2022 ASH Annual Meeting – – Data...
IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA® in Patients with Relapsed or Refractory B Cell Non-Hodgkin’s Lymphoma
November 02, 2022 16:05 ET
|
IGM Biosciences, Inc.
– Companies to Leverage Lead Product Candidate from IGM’s Proprietary IgM Antibody Platform with ZYNLONTA® for Novel Combination Therapy in Relapsed/Refractory B Cell NHL – – Phase 1 Trial Expected...
IGM Biosciences to Present at Three Upcoming Investor Conferences
September 06, 2022 07:00 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today...
IGM Biosciences Announces Second Quarter 2022 Financial Results and Provides Corporate Update
August 08, 2022 16:10 ET
|
IGM Biosciences, Inc.
– Continued Advancement in Clinical Development of Imvotamab (IGM-2323) and IGM-8444 – – Received $150 Million Upfront Payment in Connection with Closing of Collaboration Agreement with Sanofi – ...
IGM Biosciences to Present at the 2022 Jefferies Healthcare Conference
June 01, 2022 07:00 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today...
IGM Biosciences to Present at the 2022 RBC Capital Markets Global Healthcare Conference
May 10, 2022 07:00 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today...